April 21, 2014
BI Chairman Andreas Barner Boehringer Ingelheim (BI) will continue focusing on its global biosimilar business, but its full-fledged entry into the Japanese market will take time, Chairman Andreas Barner said on April 15. During an interview with media outlets including...read more